TAM
HAE icon

Third Avenue Management’s Haemonetics HAE Stock Holding History

Third Avenue Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-42,000
Closed -$1.68M – 173
2013
Q3 		$1.68M Hold
42,000
– – 0.03% 135
2013
Q2 		$1.74M Buy
+42,000
New +$1.7M 0.03% 124

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Third Avenue Management's HAE Position: Q4 2013 in Review

Third Avenue Management sold out of Haemonetics (HAE) in Q4 2013, closing a stake of 42,000 shares — an estimated $1.68M sold.

Third Avenue Management first reported a position in HAE in Q2 2013 and held it in 2 quarters. The position peaked at $1.74M in Q2 2013. 195 funds tracked by Wall St. Rank hold HAE as of Q4 2013.

  • Third Avenue Management reported no remaining Haemonetics position as of Q4 2013 after selling out during the quarter.
  • Third Avenue Management sold 42,000 Haemonetics shares in Q4 2013, an estimated $1.68M.
  • Third Avenue Management first reported a position in Haemonetics in Q2 2013 and held it in 2 quarters.
  • Third Avenue Management's Haemonetics position peaked at $1.74M in Q2 2013.
  • 195 funds tracked by Wall St. Rank held Haemonetics as of Q4 2013.

Based on Third Avenue Management's 13F filing for Q4 2013, filed 14 Feb 2014.